Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $13.99 is 21.97% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 14.15||$ 17.99|
|Low:||$ 13.87||$ 11.47|
ETFs with INVA as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.11%||SPDR S&P Pharmaceuticals ETF (XPH)||+6.90 (16.53%)|
|1.01%||iShares U.S. Pharmaceutical ETF (IHE)||+20.98 (14.36%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Innoviva, Inc. ("Innoviva", the "Company", the "Registrant" or "we" and other similar pronouns) is focused on bringing compelling medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals to maximize the potential of its respiratory assets partnered with Glaxo Group Limited ("GSK"), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, "FF/VI"),ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, "UMEC/VI") and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist ("LABA") Collaboration Agreement, we are entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion and royalties from sales of ANORO(TM) ELLIPTA(TM) tier upward at a range from 6.5% to 10%. ... More ...
Nasdaq Official Price
Aug. 17, 2018
Aug. 17, 2018